Dr. Terry Kelly is the Chief Innovation Officer for VolitionRx and Chief Scientific Officer for Volition America. She has over 15 years of experience in epigenetics including developing novel technologies and seeing them through to commercialization. Her laboratory is based in San Diego, where they use a multi-omics approach to understand the basic epigenetic mechanisms that underly normal biology and how they are mysregulated by, and contribute to, a variety of diseases including cancer and sepsis. She received her PhD in Neuroscience from UCLA, Post-doctoral fellowship in Cancer Epigenetics from USC Norris Cancer Center and has previous leadership roles in R&D and Custom product and service development. She is an active member of the local community, including sitting on advisory boards.